Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.02 USD | +2.77% | +10.23% | -10.70% |
Financials (USD)
Sales 2024 * | 58.64M | Sales 2025 * | 71.15M | Capitalization | 266M |
---|---|---|---|---|---|
Net income 2024 * | 14M | Net income 2025 * | 26M | EV / Sales 2024 * | 4.54 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.74 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
10.8
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.7% |
Latest transcript on Fennec Pharmaceuticals Inc.
1 day | +2.77% | ||
1 week | +10.23% | ||
Current month | +9.15% | ||
1 month | -4.48% | ||
3 months | +6.60% | ||
6 months | +27.32% | ||
Current year | -10.70% |
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 14-04-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 10.02 | +2.77% | 127,504 |
24-05-10 | 9.75 | +3.50% | 102,221 |
24-05-09 | 9.42 | +1.62% | 43,646 |
24-05-08 | 9.27 | -0.86% | 38,946 |
24-05-07 | 9.35 | +2.86% | 54,392 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.70% | 266M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- FENC Stock